Fundraising Fox
🦊/Companies
Sign in

Calder Biosciences

NYC, US · Founded 2018 · 4 employees on LinkedIn · 1 known investors

Find your way into Calder Biosciences

266 people in our graph share verified history with the Calder Biosciences team — schools, employers, funds. One of them is your warm intro.

David Kaufmanunlockedknows Christopher Marshall · together at The Rockefeller University (overlapped)
×6knows the team · via University at Buffalo
knows the team · via Oliver Wyman
×3knows the team · via Stony Brook University
knows the team · via The Rockefeller University

Calder Biosciences develops protein-based subunit vaccines using its 3D-Vaxlock technology, which uses dityrosine crosslinking to lock immunogens into the shape they hold on a virus surface for improved antibody responses. Its engineered immunogens aim to offer better safety, efficacy, thermostability, and reduced cold chain requirements against infectious diseases.

BiotechHealthtechMedical Devices

Founders & leadership

Calder Biosciences was founded in 2018 by Christopher Marshall and Mark A. Yondola.

CMChristopher Marshall
Christopher MarshallinFounder & CEOChristopher Marshall holds a Ph.D. in biomedical research from Rockefeller University and has founded multiple biotechnology companies, including Ophidion (addressing neurological and pain conditions) and Avatar Biotechnologies (focused on enzymes and protein technologies), before founding Calder Biosciences to develop protein-based subunit vaccines. He previously worked as a management consultant at Oliver Wyman & Co. on risk management and strategy projects for European financial institutions and is a registered USPTO patent agent.
MAMark A. Yondola
Mark A. YondolainFounder & Chief Science OfficerMark Yondola brings over 15 years of experience in protein engineering and vaccine design, with expertise in CMC process design, analytical characterization, and CDMO management for protein biologics. As Founder and Chief Science Officer of Calder Biosciences, he leads development of protein-based vaccines using the company's 3D-Vaxlock technology platform.
DPDirk Pleimes
Dirk PleimesinChief Medical Officer

Investors · 1

SOSVNew York · $30K – $550K

Competitors · 1

by search overlap
Coya Therapeutics3 shared keywordsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.

Companies competing with Calder Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2.9M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$299.7K
National Institutes of Health (NIH)National Institutes of HealthPhase II2018$2.9M
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$599.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Calder Biosciences do?
Calder Biosciences develops protein-based subunit vaccines using its 3D-Vaxlock technology, which uses dityrosine crosslinking to lock immunogens into the shape they hold on a virus surface for improved antibody responses. Its engineered immunogens aim to offer better safety, efficacy, thermostability, and reduced cold chain requirements against infectious diseases.
Who founded Calder Biosciences?
Calder Biosciences was founded by Christopher Marshall, Mark A. Yondola in 2018.
Who are Calder Biosciences's investors?
Calder Biosciences's investors include SOSV.
Where is Calder Biosciences headquartered?
Calder Biosciences is headquartered in NYC, US.